A small Dallas biotech company and the University of Texas took on big pharma and won.
A federal jury in Delaware found that Boston Scientific infringed on a patent related to coronary stents held by the University of Texas and exclusively licensed to TissueGen and must pay $42 million in damages to the two plaintiffs.
The medical device giant infringed on the patent with its “Synergy” brand coronary stents, which are often used to treat narrowed coronary arteries. The company was the first to get FDA approval for a bioabsorbable polymer drug-eluting stent, which means it’s coated with a slow-release medication to help prevent blood clotting.
